// App-Quantinova.ai

: Management of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Proteasome Inhibitor Based Therapy at First Relapse in Routine Clinical Practice in Germany

Researchers

Presenter

  • H. Tilman Steinmetz

Principal Investigators

  • Moushmi Singh

  • Andrea Lebioda

  • Aurelien Mantonnier

  • Leah Fink

  • Achim Rieth

  • Florence Suzan

  • Sebastian Gonzalez-McQuire

Medical Centers

  • Center for Hematology and Oncology, Cologne, DEU

  • Amgen, Ltd., Uxbridge, United Kingdom

  • Amgen GmbH, Munich, Germany

  • Kantar Health, Paris, France

  • Amgen GmbH, Munich, DEU

  • Amgen (Europe) GmbH, Zug, Switzerland

Locations

  • United Kingdom

  • Germany

  • France

  • Switzerland

Companies

  • Amgen GmbH

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved